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Elective Cancer Surgery in COVID-19–Free
Surgical Pathways During the SARS-CoV-2
Pandemic: An International, Multicenter,
Comparative Cohort Study
James C. Glasbey, MBBCh, BSc, MRCS, PGCert1 and Aneel Bhangu, MBChB, PhD2, on behalf of the COVIDSurg Collaborative
abstract
PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to
determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free
surgical pathways were associated with lower postoperative pulmonary complication rates compared with
hospitals with no defined pathway.
PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective
surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included
patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined
as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and
inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with
COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute
respiratory distress syndrome, unexpected ventilation).
RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free
surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with
fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major
surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways
(2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses
for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and
patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also
lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76).
CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to
provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks.
J Clin Oncol 38. © 2020 by American Society of Clinical Oncology
INTRODUCTION
During the initial phases of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) pandemic, an
estimated 2.3 million cancer operations worldwide were
postponed because of the risk of in-hospital trans-
mission.1 Perioperative SARS-CoV-2 is associated with
a high risk of pulmonary complications and death.2-5
Elective surgical activity was reduced to increase criti-
cal care capacity for patients with coronavirus disease
2019 (COVID-19) and to release surgical teammembers
to support wider hospital responses.6-8 However, some
elective surgery for time-sensitive conditions continued,
with prioritization of patients with resectable cancers at
risk for progression and patients for whom alternative
treatment modalities would be ineffective.9-11
Before the pandemic, most cancer surgery was per-
formed in hospitals that also supported acute medical
services.12-14 Such hospitals have admitted patients
with COVID-19 during the pandemic, increasing the
risk of cross infection of elective surgery patients. To
avoid this, some health care providers have estab-
lished dedicated COVID-19–free surgical pathways,
which deliver surgery, critical care, and inpatient ward
care with no shared areas with patients with COVID-19.
Major reorganization of hospital services to provide
COVID-19–free surgical pathways for elective cancer
surgery needs to be justified because it will carry
significant costs for providers and patients. Informa-
tion is urgently required to determine whether these
pathways reduce adverse postoperative outcomes.
This study aimed to compare the rate of postoperative
pulmonary complications after elective cancer oper-
ations in COVID-19–free surgical pathways and hos-
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PATIENTS AND METHODS
Study Design and Protocol
This was an international, multicenter cohort study of adults
who underwent elective cancer surgery. Local principal
investigators were responsible for obtaining clinical audit,
institutional review board, or ethical approval in line with
local and national regulations. For example, in the United
Kingdom, the study was registered as a clinical audit at
each participating hospital, whereas in other countries,
such as Saudi Arabia, nationwide ethics approval was
granted. Data were collected online and stored on a secure
data server running the Research Electronic Data Capture
web application.15
Centers and Settings
Hospitals that performed elective cancer surgery in areas
affected by the COVID-19 pandemic were eligible to par-
ticipate. Enrollment of consecutive patients commenced
from the date of admission of the first patient with SARS-
CoV-2 to the participating hospital or, in the case of COVID-
19–free surgical pathways in hospitals where no cases had
been recorded, to the nearest hospital treating patients with
COVID-19.
Each patient was classified as having undergone surgery
within a COVID-19–free surgical pathway or with no defined
pathway. To determine whether a COVID-19–free surgical
pathway was used, an assessment was made of the op-
erating room, critical care, and inpatient ward areas where
each patient was treated. Patients were classified as being
treated within a COVID-19–free pathway if there was
a policy of complete segregation in all three areas away
from patients with COVID-19. Patients were classified as
being treated within no defined pathway if in any one of
these areas was shared with patients with COVID-19. The
classification was based on whether there was a policy of
segregation in place rather than whether individual elective
patients came into contact with patients with COVID-19
because asymptomatic SARS-CoV-2 infection is common,
so contact with an infectious patient was possible even if
this was not known at the time. COVID-19–free surgical
pathways could be provided by hospitals that only provided
elective care, including specialized units set up during the
pandemic. Alternatively, they could be provided by acute
hospitals that designated separate COVID-19–free areas
and COVID-19 treatment areas to ensuring that there were
no shared areas. In any particular hospital, it was possible
that some patients were treated within a COVID-19–free
surgical pathway, whereas others had no defined pathway
(eg, where a COVID-19–free surgical pathway was in-
troduced part way through the study inclusion period), and
our patient-level classification captured this. Figure 1
shows examples of COVID-19–free surgical pathways
and no defined pathways.
Surgical Pathway Components
To better understand health system responses to the
COVID-19 pandemic, additional data points were in-
troduced on April 2, 2020, to capture data on individual
components of the surgical pathway (operating room,
critical care, inpatient ward). These were completed for
consecutive patients after this date.
Patients and Procedures
Adult patients (age $ 18 years) who underwent elective
surgery with curative intent for a suspected cancer were
included from emergence of COVID-19 up to April 19,
2020. Patients were identified preoperatively from multi-
disciplinary team (MDT) meeting (or tumor board) lists and
the subsequent operation location identified by the oper-
ating surgeon. Patients were followed up to postoperative
day 30, with the day of surgery being day 0. All consecutive
CONTEXT
Key Objective
Surgical providers have begun to create COVID-19–free surgical pathways in both separate elective hospitals and major
acute hospitals in which elective operating room, critical care, and inpatient ward areas are not shared with patients with
COVID-19. Major service redesign to provide these pathways is expensive and difficult; evidence is urgently needed to
inform clinical practice.
Knowledge Generated
Our data demonstrated that pulmonary complication rates, SARS-CoV-2 infection rates, and mortality rates were con-
sistently lower for patients within COVID-19–free surgical pathways. These findings persisted after risk adjustment,
sensitivity analyses of low-risk patients and propensity score–matched groups, and patients who had a negative pre-
operative SARS-CoV-2 test. Differences in outcomes were observed in both high and low SARS-CoV-2 incidence areas.
Relevance
As health providers restart elective cancer surgery, they should prevent harm by investing in dedicated COVID-19–free
surgical pathways tailored to local resources available.
2 © 2020 by American Society of Clinical Oncology
Glasbey and Bhangu
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on December 7, 2020 from 147.188.216.057
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
patients who underwent eligible surgery were included
(Data Supplement, online only). Eligible cancers included
colorectal, esophagogastric, head and neck (oral, oro-
pharyngeal, laryngeal, hypopharyngeal, salivary, thyroid,
paranasal sinus, skin), thoracic (lung, pleural, mediastinal,
chest wall), hepatopancreatobiliary (liver, pancreatic),
urologic (prostate, bladder, renal), gynecologic (uterine,
ovarian, cervical, vulvar, vaginal), and breast as well as
sarcoma (soft tissue, bony) and intracranial malignancies
(Data Supplement). Participating centers could contribute
data for either single or multiple cancers depending on local
services and capacity.16 Patients who had clinical symp-
toms consistent with COVID-19 or who were confirmed to
have SARS-CoV-2 infection (by quantitative reverse tran-
scription polymerase chain reaction and/or positive tho-
racic computed tomography [CT] imaging performed within
72 hours before surgery) at the time of surgery were
excluded.
Data Variables
To account for different tumor grading and staging systems
across solid cancers, disease status was classified as early
stage (organ confined, non-nodal, nonmetastatic, fully
resectable) or advanced stage (growth beyond organ,
nodal, metastatic operated with curative intent). Full defi-
nitions are provided in the Data Supplement. Grade of
surgery was categorized on the basis of the Clinical Coding
& Schedule Development Group as either minor (minor/
intermediate) or major (major/complex major).17,18 Pre-
operative testing was defined as a swab test and/or thoracic
CT imaging performed in the 72 hours before surgery to
confirm SARS-CoV-2 status.
Outcome Measures
The primary outcome measure was the rate of post-
operative pulmonary complications within 30 days after
surgery. This included pneumonia, acute respiratory dis-
tress syndrome, and/or unexpected postoperative ventila-
tion (Data Supplement19). The secondary outcomes were
postoperative SARS-CoV-2 infection and mortality within
30 days after surgery. Postoperative SARS-CoV-2 infection
was defined as a positive swab, positive thoracic CT im-
aging, or a clinical diagnosis of symptomatic COVID-19 in

























































FIG 1. Differences between hospitals with a coronavirus disease 2019 (COVID-19)–free surgical pathway and hospitals with no defined pathway.
COVID-19–free surgical pathways: complete segregation of operating room, critical care, and inpatient ward areas for elective cancer surgery away
from patients being treated for COVID-19. No defined pathways: hospitals where there was mixing of patients who were undergoing treatment for
COVID-19 and elective surgical patients in any operating room, critical care, or inpatient ward area. ICU, intensive care unit.
Journal of Clinical Oncology 3
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Community SARS-CoV-2 Incidence
The community SARS-CoV-2 incidence within each par-
ticipating hospital’s local community was extracted from
WHO,20 European Centre for Disease Prevention and
Control,21 or US Centers for Disease Control and Pre-
vention22 statistics. SARS-CoV-2 incidence was calculated
for 2-week windows in March and April 2020 on the basis of
the number of confirmed SARS-CoV-2 cases at the smallest
available administrative level (city, region, or country).23
Hospitals were classified as being in communities with
either low (, 25 cases per 100,000 population) or high
($ 25 cases per 100,000 population) SARS-CoV-2 in-
cidence (Data Supplement).
Data Integrity
Previous international outcomes studies have achieved
. 95%case ascertainment and. 98%data accuracy during
external validation.24 We identified low-volume centers
(predefined as five or fewer patients per participating
specialty) and asked local principal investigators to confirm
case ascertainment against MDT records. If a specialty
within a hospital was found to have incomplete case as-
certainment, any data entered from this specialty were
excluded from analysis.
Statistical Analysis
The study was conducted according to Strengthening the
Reporting of Observational Studies in Epidemiology25 and
reported according to Statistical Analyses and Methods in
the Published Literature.26 Nonparametric data were
summarized with medians and interquartile ranges, and
differences between groups were tested using the Mann-
Whitney U test. The x2 test was used for categorical data.
Missing data were included in flowcharts and summary
tables, which allowed denominators to remain consistent in
calculations.
Bayesian univariable and multivariable mixed-effects lo-
gistic regression was used to calculate odds ratios (ORs)
and 95% CIs. Clinically plausible patient-, disease-, op-
eration-, and location-specific factors were selected a priori
for inclusion in adjusted analyses to identify independent
predictors of postoperative pulmonary complications (pri-
mary outcome). Country was included as a random effect in
both the unadjusted and the adjusted models. An ex-
ploratory analysis was conducted of the association be-
tween components of the COVID-19–free surgical pathway
and the primary outcome measure. Analyses were carried
out using R version 3.1.1 packages finalfit, tidyverse, and
BRMS27 (R Foundation for Statistical Computing, Vienna,
Austria; Data Supplement).
Sensitivity Analyses
We anticipated a selection bias, with lower-risk patients
being more likely to be treated within COVID-19–free
surgical pathways. To account for this risk of bias, we
explored differences in the postoperative pulmonary
complications stratified by three common risk factors (age,
sex, and American Society of Anesthesiologists [ASA]
grade); performed a sensitivity analysis for pulmonary
complications, including low-risk (ASA grade 1 or 2) pa-
tients only; and performed propensity score matching using
a nearest neighbor method, including patients within
COVID-19–free surgical pathways in a 1:1 ratio with those
with no defined pathway (Data Supplement). To exclude
a potential confounding effect of presymptomatic carriage
of SARS-CoV-2 in the association between hospital type
and the primary outcome, we performed a further sensitivity
analysis that included only patients with a negative pre-
operative SARS-CoV-2 swab test.
RESULTS
Patients and Procedures
At the time of this analysis (June 15, 2020), a total 9,171
patients from 445 hospitals were included. These patients
were from the United Kingdom (29.2%; 2,679 patients),
Italy (17.3%; 1,583 patients), Spain (8.3%; 764 patients),
United States (6.3%; 574 patients), and 50 other countries.
Overall, 39.2% of patients (3,698) were male, 17.9%
(1,644) were age , 50 years, and 8.3% (761) were age
$ 80 years. Complete baseline patient, disease, and op-
erative characteristics are listed in Table 1.
A total of 2,481 patients (27.1%) underwent surgery within
COVID-19–free surgical pathways, and 6,689 (72.9%)
underwent surgery within no defined pathway. Patients
in COVID-19–free surgical pathways were younger, had
fewer comorbidities, and had better performance scores.
Major surgery accounted for 75.6% (1,866 of 2,481) of
operations in COVID-19–free surgical pathways and
77.7% (5,179 of 6,689) where there was no defined
pathway; a full list of operations performed is provided in
the Data Supplement. The missing data rates were low
(Data Supplement). Changes in local SARS-CoV-2 in-
cidence over the study period are listed in the Data
Supplement.
Preoperative Testing
Overall, 27.0% (2,473 of 9,409) of patients underwent
preoperative SARS-CoV-2 testing; 75.9% (1,878 of 2,473)
of these were performed using a swab test. The pre-
operative testing rate was higher in COVID-19–free surgical
pathways versus no defined pathway (39.1% [970] v
22.5% [1,503]; P , .0001).
Postoperative Pulmonary Complications
The overall 30-day pulmonary complication rate was
4.2% (385 of 9,171), which was lower for patients within
a COVID-19–free surgical pathway than within no defined
pathway (2.2% [55 of 2,481] v 4.9% [329 of 6,689];
unadjusted OR, 0.49; 95% CI, 0.36 to 0.66). After ad-
justment, surgery in a COVID-19–free surgical pathway
remained associated with a lower postoperative pulmonary
4 © 2020 by American Society of Clinical Oncology
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TABLE 1. Characteristics of Patients Treated Within COVID-19–Free Surgical Pathways and With No Defined Pathway
Characteristic COVID-19–Free Surgical Pathway, No. (%) No Defined Pathway, No. (%) P
No. of patients 2,481 6,689
Age, years
, 50 558 (22.5) 1,086 (16.2) , .001
50-59 576 (23.2) 1,404 (21.0)
60-69 633 (25.5) 1,911 (28.6)
70-79 552 (22.2) 1,689 (25.3)
$ 80 162 (6.5) 599 (9.0)
Sex
Female 1,743 (70.3) 3,832 (57.3) , .001
Male 737 (29.7) 2,856 (42.7)
Missing 1 1
BMI
Normal 996 (40.1) 2,542 (38.0) .050
Overweight 796 (32.1) 2,091 (31.3)
Obese 469 (18.9) 1,443 (21.6)
Underweight 53 (2.1) 164 (2.5)
Missing 167 (6.7) 449 (6.7)
ASA grade
1-2 1,959 (79.2) 4,640 (69.7) , .001
3-5 515 (20.8) 2,016 (30.3)
Missing 7 33
RCRI
0 949 (38.3) 1,942 (29.0) , .001
1 1,181 (47.6) 3,453 (51.6)
2 306 (12.3) 1,023 (15.3)
$ 3 45 (1.8) 271 (4.1)
Respiratory comorbidity
No 2,249 (90.6) 5,929 (88.6) .007
Yes 232 (9.4) 760 (11.4)
ECOG PS
0 1,657 (67.1) 4,087 (62.2) , .001
1-2 775 (31.4) 2,367 (36.0)
3-4 36 (1.5) 115 (1.8)
Missing 13 120
Cancer type
Colorectal 437 (17.6) 1,873 (28.0) , .001
Breast 827 (33.3) 1,313 (19.6)
Gynecologic 330 (13.3) 772 (11.5)
Head or neck 253 (10.2) 884 (13.2)
Hepatopancreatobiliary 161 (6.5) 515 (7.7)
Intracranial 34 (1.4) 130 (1.9)
Thoracic 172 (6.9) 385 (5.8)
Esophagogastric 75 (3.0) 312 (4.7)
Sarcoma 118 (4.8) 143 (2.1)
Urologic 74 (3.0) 362 (5.4)
(continued on following page)
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complication rate (adjusted OR [aOR], 0.62; 95% CI, 0.44 to
0.86). Older age, male sex, ASA grades 3-5, poorer per-
formance status, higher cardiac risk, preexisting respiratory
disease, advanced disease stage, major surgery, esoph-
agogastric surgery, and surgery in high SARS-CoV-2 in-
cidence areas were also associated with a greater odds of
pulmonary complications (Fig 2; Table 2; Data Supplement).
Sensitivity Analyses
Postoperative pulmonary complication rates stratified by
age, sex, and ASA grade in hospitals with and without
COVID-19–free surgical pathways are shown in the Data
Supplement. In a sensitivity analysis including only low-risk
patients (n 5 6,489), COVID-19–free surgical pathways
remained associated with a reduced odds of pulmonary
complications (aOR, 0.58; 95% CI, 0.36 to 0.93; Data
Supplement).
Propensity score matching created well-balanced groups
(Data Supplement), with 2,449 patients within COVID-
19–free surgical pathways matched to 2,449 with no de-
fined pathway. After adjustment, surgery within a COVID-
19–free surgical pathway was associated with a lower odds
of pulmonary complications (aOR, 0.65; 95% CI, 0.44 to
0.96; Data Supplement). In a sensitivity analysis including
only patients with a negative preoperative SARS-CoV-2 test
(n 5 2,447), again a COVID-19–free surgical pathway was
associated with lower pulmonary complication rates (aOR,
0.52; 95% CI, 0.29 to 0.91; Data Supplement).
Surgical Pathway Components
Consecutive data were available for 4,505 patients. Of
these, 45.6% (2,053) were classified as having a COVID-
19–free surgical pathway. Of 2,451 patients with no defined
pathway, 86.5% (2,120) had an operating room, 21.5%
(526) a critical care area, and 59.8% (1,466) had a ward
space shared with patients with COVID-19. Treatment in
both a COVID-19–free ward and a critical care area (aOR,
0.43; 95% CI, 0.24 to 0.77) or a complete COVID-19–free
surgical pathway (aOR, 0.30; 95% CI, 0.17 to 0.54) was
significantly associated with a lower odds of pulmonary
complications versus treatment in shared operating room,
critical care, and ward areas (Data Supplement).
Postoperative SARS-CoV-2 Infection
The overall rate of postoperative SARS-CoV-2 infection was
3.2% (291 of 9,171). A majority was confirmed with a swab
TABLE 1. Characteristics of Patients Treated Within COVID-19–Free Surgical Pathways and With No Defined Pathway (continued)
Characteristic COVID-19–Free Surgical Pathway, No. (%) No Defined Pathway, No. (%) P
Disease stage
Early 1,822 (73.5) 4,707 (70.4) .004
Advanced 657 (26.5) 1,978 (29.6)
Missing 0.08 0.06
Booking type
Day case 206 (8.4) 524 (7.9) .493
Inpatient 2,259 (91.6) 6,117 (92.1)
Missing 0.6 0.08
Anesthetic
Regional/local 99 (4.0) 388 (5.8) .001
General 2,382 (96.0) 6,301 (94.2)
Operation grade
Minor 601 (24.4) 1,488 (22.3) .042
Major 1,866 (75.6) 5,179 (77.7)
Missing 0.6 0.3
Preoperative testing
Not screened 1,511 (60.9) 5,186 (77.5) , .001
Screened 970 (39.1) 1,503 (22.5)
Community SARS-CoV-2 risk
Low 1,948 (78.5) 6,079 (90.9) , .001
High 533 (21.5) 610 (9.1)
NOTE. See the Data Supplement for full definitions. Percentages calculated as a proportion of column total. P values calculated using x2 test.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; COVID-19, coronavirus disease 2019; ECOG PS, Eastern
Cooperative Oncology Group performance status; RCRI, Revised Cardiac Risk Index; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
6 © 2020 by American Society of Clinical Oncology
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Variable
Pulmonary Complications Rate,
No. of Total No. (%) OR 95% CI
0–4 –2 2 4
Log OR
Age, years




  > 80
20 of 1,644 (1.2)
51 of 1,980 (2.6)
118 of 2,545 (4.6)
145 of 2,241 (6.5)
51 of 761 (6.7)
Reference
1.44      0.86 to 2.52
1.90      1.18 to 3.17 
2.11      1.30 to 3.47 
1.96      1.11 to 3.52
Sex
  Female 121 of 5,576 (2.2) Reference







135 of 3,538 (3.8)
117 of 2,888 (4.1)
85 of 1,912 (4.5)
10 of 217 (4.6)
38 of 616 (6.2)
Reference
1.02      0.78 to 1.33
1.06      0.79 to 1.43
1.10      0.51 to 2.20




192 of 6,600 (2.9)
191 of 2,531 (7.6)
Reference





  Head or neck
  Hepatopancreatobilary
  Intracranial




134 of 2,310 (5.8)
9 of 2,141 (0.4)
20 of 1,102 (1.8)
41 of 1,137 (3.6)
50 of 676 (7.4)
2 of 164 (1.2)
41 of 557 (7.4)
65 of 387 (16.8)
8 of 261 (3.1)
15 of 436 (3.4)
Reference
0.30      0.12 to 0.71
0.61      0.37 to 1.01
1.35      0.75 to 2.34
1.40      0.97 to 2.00
0.33      0.04 to 1.42
1.05      0.70 to 1.53
3.45      2.39 to 4.91
0.99      0.41 to 2.07





148 of 5,745 (2.6)
220 of 3,142 (7.0)
15 of 151 (9.9)
Reference
1.67      1.28 to 2.15




332 of 8,187 (4.1)
67 of 1,012 (6.6)
Reference




321 of 8,164 (3.9)
64 of 1,007 (6.4)
Reference






33 of 2,892 (1.1)
221 of 4,634 (4.8)
89 of 1,329 (6.7)
42 of 316 (13.3)
Reference
1.69      0.91 to 3.02
1.72      0.88 to 3.30




27 of 2,089 (1.3)
356 of 7,045 (5.1)
Reference




222 of 6,530 (3.4)
163 of 2,635 (6.2)
Reference
1.43      1.14 to 1.80
Preoperative SARS-CoV-2 tested
  No 286 of 6,698 (4.3) Reference
  Yes 99 of 2,473 (4.0) 0.92      0.70 to 1.20
Hospital type
  No defined pathway
  COVID–19–free surgical pathway
329 of 6,689 (4.9)
55 of 2,481 (2.2)
Reference




334 of 8,028 (4.2)
51 of 1,143 (4.5)
Reference
1.42      0.96 to 2.15
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test (85.6%; 249 of 291). The SARS-CoV-2 infection rate
was lower in COVID-19–free surgical pathways (2.1%; 53 of
2,481) than with no defined pathway (3.6%; 238 of 6,820;
aOR, 0.53; 95% CI, 0.36 to 0.76). This was consistent in
a sensitivity analysis with swab testing only (aOR, 0.44;
95% CI, 0.28 to 0.68; Data Supplement) and was con-
sistent across hospitals in high (3.9% v 8.2%) and low
SARS-CoV-2 incidence areas (1.6% v 3.1%; Table 3).
SARS-CoV-2 infection was associated with increased pul-
monary complication rates compared with patients without
infection (33.8% [130 of 385] v 1.8% [161 of 8,786]; OR,
29.78; 95% CI, 22.4 to 39.6).
Postoperative Mortality
The overall postoperative mortality rate was 1.5% (134 of
9,115). Mortality was higher in patients with pulmonary
complications (OR, 25.64; 95% CI, 17.63 to 36.67) and in
patients with SARS-CoV-2 infection (OR, 29.34; 95% CI,
20.13 to 43.04). It was lower in patients operated on in
COVID-19–free surgical pathways (OR, 0.45; 95% CI, 0.25
to 0.78). Of the 30-day deaths, 49.3% (66 of 134) were
associated with pulmonary complications, and 44.0% (59
of 134) were associated with SARS-CoV-2 infection (Fig 3).
Mortality was higher after pulmonary complications in
patients with SARS-CoV-2 (30.8%; 40 of 130) than in
patients without infection with pulmonary complications
(10.7%; 26 of 244).
DISCUSSION
This study identified that postoperative pulmonary com-
plication rates were lower for patients in COVID-19–free
surgical pathways during the SARS-CoV-2 pandemic.
Despite a tendency for lower-risk surgeries to be performed
in these pathways, effects persisted after risk adjustment,
sensitivity analyses, and propensity score matching. The
advantage of COVID-19–free pathways was also seen in
patients with a negative SARS-CoV-2 test preoperatively.
Older patients, males, and patients with cardiorespiratory
comorbidities were consistently at greater risk of adverse
outcomes. Mortality was primarily driven by pulmonary
complications, which was low in COVID-19–free surgical
pathways and high with postoperative SARS-CoV-2 in-
fection. Overall, these data support major international
redesign of surgical services, based on local available re-
sources, to provide elective cancer surgery in COVID-
19–free surgical pathways. While the greatest effect size
was seen in areas of high SARS-CoV-2 incidence, there was
also a significant difference in outcomes in low-incidence
areas. Setup of COVID-19–free pathways is therefore likely
to be justified during the end phases of current lockdowns
in preparation for future wave.
It is likely that differences in SARS-CoV-2 transmission rates
are responsible for differences in pulmonary complications
between hospitals with COVID-19–free surgical pathways
and those with no defined pathway. First, the rate of post-
operative SARS-CoV-2 infection was consistently lower in
COVID-19–free surgical pathways. Second, SARS-CoV-2
infection was associated with a very high rate of pulmonary
complications. Third, the benefit of COVID-19–free pathways
was greatest in high SARS-CoV-2 incidence areas. Finally,
the effect size increased in proportion with the number of
COVID-19–free components of the surgical pathway. The
overall preoperative testing rate was low (27.0%), and testing
was not associated with lower pulmonary complication rates
in the main model. Furthermore, in a sensitivity analysis for
patients with a negative preoperative swab test, the benefit of
COVID-19–free pathways persisted.
Although we defined COVID-19–free pathways in the pro-
tocol, the exact nature varied across this pragmatic study.
For example, we did not include elective and emergency
admission areas or the perioperative recovery room in the
definition of center status. Patients with comorbidities and
who are elderly will still need to undergo surgery in major
acute hospitals because of resource availability (eg, critical
care, interventional radiology, multispecialty operations), and
these hospitals are likely to continue to admit patients with
COVID-19. COVID-19–free pathways must be robustly
quality assured within these settings. Detailed evaluations of
additional in-hospital measures to reduce SARS-CoV-2 ex-
posure, including serial preoperative testing, personal pro-
tective equipment, drug prophylaxis, staff testing, and
perioperative isolation, are still required.
The overall mortality rate with pulmonary complications
(17.2%) is higher than would be expected compared with
prepandemic rates.22-27,28 Data from elective and emergency
surgical patients have shown high mortality associated with
perioperative SARS-CoV-2 infection, which is consistent with
our series.5 This information should be used routinely as part
of informed consent for elective surgery.
There were limitations to this study. First, the risk of
selection bias in COVID-19–free surgical pathways was
accounted for through risk adjustment and planned
sensitivity analyses. Despite this, COVID-19–free path-
ways may have been better resourced, and there may
have been residual bias. However, establishing COVID-
19–free areas did not seem to be determined by re-
source availability alone; patients were operated on
in these pathways in 27 of 37 countries in which five
FIG 2. Factors associated with postoperative pulmonary complications after elective cancer surgery, including data from 8,971 patients with complete data.
See Data Supplement for the full model, details aroundmissing data, and full definitions. ASA, American Society of Anesthesiologists; BMI, bodymass index;
COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group; OR, odds ratio; RCRI, Revised Cardiac Risk Index; SARS-CoV-2, severe
acute respiratory syndrome coronavirus 2.
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TABLE 2. Comparison of Patients With and Without Postoperative Pulmonary Complications
Factor No Pulmonary Complications, No. (%) Pulmonary Complications, No. (%) P
No. of patients 8,786 385
Age, years
, 50 1,624 (18.5) 20 (5.2) , .001
50-59 1,929 (22.0) 51 (13.2)
60-69 2,427 (27.6) 118 (30.6)
70-79 2,096 (23.9) 145 (37.7)
$ 80 710 (8.1) 51 (13.2)
Sex
Female 5,455 (62.1) 121 (31.4) , .001
Male 3,329 (37.9) 264 (68.6)
Missing 2 0
BMI
Normal 3,403 (38.7) 135 (35.1) .100
Overweight 2,771 (31.5) 117 (30.4)
Obese 1,827 (20.8) 85 (22.1)
Underweight 207 (2.4) 10 (2.6)
Missing 578 (6.6) 38 (9.9)
ASA grade
1-2 6,408 (73.3) 192 (50.1) , .001
3-5 2,340 (26.7) 191 (49.9)
Missing 38 2
Current smoker
No 7,843 (89.3) 321 (83.4) , .001
Yes 943 (10.7) 64 (16.6)
Preexisting respiratory condition
No 7,873 (89.6) 306 (79.5) , .001
Yes 913 (10.4) 79 (20.5)
RCRI
0 2,859 (32.5) 33 (8.6) , .001
1 4,413 (50.2) 221 (57.4)
2 1,240 (14.1) 89 (23.1)
$ 3 274 (3.1) 42 (10.9)
ECOG PS
0 5,597 (64.7) 148 (38.6) , .001
1-2 2,922 (33.8) 220 (57.4)
3-4 136 (1.6) 15 (3.9)
Missing 131 2
(continued on following page)
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or more centers participated. Second, we included swab,
CT, and clinical diagnoses of COVID-19 in the defini-
tion of postoperative SARS-CoV-2 infection to reflect
variable access to testing during early phases of the
pandemic.29,30 However, only 14.4% of patients infected
had a CT or clinical diagnosis, which minimizes the risk
of incorrect diagnosis. Third, borderline operable can-
cers and high-risk patients may not have been offered
TABLE 2. Comparison of Patients With and Without Postoperative Pulmonary Complications (continued)
Factor No Pulmonary Complications, No. (%) Pulmonary Complications, No. (%) P
Cancer type
Colorectal 2,176 (24.8) 134 (34.8) , .001
Breast 2,132 (24.3) 9 (2.3)
Gynecologic 1,082 (12.3) 20 (5.2)
Head or neck 1,096 (12.5) 41 (10.6)
Hepatopancreatobiliary 626 (7.1) 50 (13.0)
Intracranial 162 (1.8) 2 (0.5)
Thoracic 516 (5.9) 41 (10.6)
Esophagogastric 322 (3.7) 65 (16.9)
Sarcoma 253 (2.9) 8 (2.1)
Urologic 421 (4.8) 15 (3.9)
Disease stage
Early 6,308 (71.8) 222 (57.7) , .001
Advanced 2,472 (28.2) 163 (42.3)
Missing 6 0
Booking type
Day case 729 (8.4) 1 (0.3) , .001
Inpatient 7,994 (91.6) 383 (99.7)
Missing 63 1
Anesthetic
Regional/local 458 (5.2) 29 (7.5) .061
General 8,328 (94.8) 356 (92.5)
Operation grade
Minor 2,062 (23.6) 27 (7.0) , .001
Major 6,689 (76.4) 356 (93.0)
Missing 35 2
Preoperative testing
Not screened 6,412 (73.0) 286 (74.3) .612
Screened 2,374 (27.0) 99 (25.7)
Hospital type
COVID-19–free surgical pathway 2,426 (27.6) 55 (14.3) , .001
No defined pathway 6,360 (72.4) 329 (85.7)
Missing 0 1
Community SARS-CoV-2 risk
Low 7,694 (87.6) 334 (86.8) .692
High 1,092 (12.4) 51 (13.2)
NOTE. See the Data Supplement for full definitions. Percentages calculated as a proportion of column total. P values calculated using x2 test.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; COVID-19, coronavirus disease 2019; ECOG PS, Eastern
Cooperative Oncology Group performance status; RCRI, Revised Cardiac Risk Index; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2.
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surgery during the pandemic, so the potential benefits of
COVID-19–free surgical pathways may be even greater
for this group.31,32 Fourth, there is a possibility of in-
complete case ascertainment, although we implemented
a number of strategies to minimize this.
COVID-19–free surgical pathways and entirely separate
elective surgery hospitals may lead to unintended conse-
quences that include reduction in capacity for other health
conditions. These consequences will need to be monitored
at a whole-system level.
COVID-19 "cold" surgical unit
(n = 2,481; 27.1%)
Mortality: 0.7% (18 of 2,466)
Pulmonary complications: 2.2% (55 of 2,481)
COVID-19 "hot" surgical unit
(n = 6,689; 72.9%)
Mortality: 1.7% (116 of 6,649)
Pulmonary complications: 4.9% (329 of 6,689)
Elective cancer surgery
(N = 9,171)
Mortality: 1.5% (134 of 9,171)
Pulmonary complications: 4.2% (385 of 9,171)
Postoperative
SARS-CoV-2 diagnosis
(n = 53; 2.1%)
Pulmonary complications:
35.9% (19 of 53)
Mortality: 11.5% (6 of 52)
No
SARS-CoV-2 diagnosis
(n = 2,428; 97.9%)
Pulmonary complications:
1.5% (36 of 2,428)
Mortality: 0.5% (12 of 2,414)
Postoperative
SARS-CoV-2 diagnosis
(n = 238; 3.6%)
Pulmonary complications:
46.6% (111 of 238)
Mortality: 22.7% (53 of 238)
No
SARS-CoV-2 diagnosis
(n = 6,451; 96.4%)
Pulmonary complications:
3.4% (218 of 6,451)




0.6% (N = 56)
Hospital type
missing
< 0.01% (N = 1)
FIG 3. Rates of pulmonary complications, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and death in hospitals with coronavirus disease
2019 (COVID-19)–free surgical pathways v those with no defined pathway. Pulmonary complications were defined as pneumonia, acute respiratory distress
syndrome, and/or unexpected postoperative ventilation.
TABLE 3. Clinical Outcomes for Patients WhoUnderwent Surgery in a COVID-19–Free Surgical Pathway Versus No Defined Pathway Split by Low





Community SARS-CoV-2 Incidence Area % (95% CI) No. of Total No. % (95% CI) No. of Total No.
Low
Pulmonary complications 2.2 (1.6 to 3.0) 43 of 1,948 4.8 (4.2 to 5.3) 290 of 6,079
SARS-CoV-2 infection 1.6 (1.1 to 2.3) 32 of 1,948 3.1 (2.7 to 3.6) 188 of 6,079
30-day mortality 0.7 (0.4 to 1.2) 14 of 1,939 1.7 (1.4 to 2.1) 103 of 6,041
30-day mortality and SARS-CoV-2 infection 0.01 (0.001 to 0.04) 2 of 1,939 0.7 (0.5 to 1.0) 44 of 6,041
High
Pulmonary complications 2.3 (1.2 to 3.9) 12 of 533 6.4 (4.6 to 8.6) 39 of 610
SARS-CoV-2 infection 3.9 (2.5 to 6.0) 21 of 533 8.2 (6.1 to 10.7) 50 of 610
30-day mortality 0.9 (0.3 to 2.2) 5 of 527 2.1 (1.1 to 3.6) 13 of 608
30-day mortality and SARS-CoV-2 infection 0.8 (0.2 to 1.9) 4 of 527 1.4 (0.7 to 2.8) 9 of 608
NOTE. Pulmonary complications were defined as pneumonia, acute respiratory distress syndrome, and/or unexpected postoperative
ventilation. Areas defined as high (30-day cumulative notification rate of $ 25 cases per 100,000 population) or low (14-day cumulative
notification rate of, 25 cases per 100,000 population) according to European Centre for Disease Control and Prevention reporting criteria during
2-week periods in March and April 2020. Proportions are presented as mean averages with 95% CIs calculated using the Pearson-Klopper exact
method (R package binom.confint).
Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
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